<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393820</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0130/1205</org_study_id>
    <secondary_id>2012-004408-36</secondary_id>
    <nct_id>NCT02393820</nct_id>
  </id_info>
  <brief_title>Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma</brief_title>
  <acronym>PACSA (ORL02)</acronym>
  <official_title>Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, multicenter, single arm phase II study, set up in collaboration with the REFCOR,
      evaluating the activity and safety of single agent pazopanib in recurrent or metastatic
      tumors in salivary gland including adenoid cystic carcinoma (ACC) and to exploring the
      activity and safety of pazopanib in non-adenoid cystic carcinoma (non-ACC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the non-ACC SGCHN population, assessment of the activity of pazopanib is exploratory
      without a predetermined study design, with up to 20 patients. A planned interim analysis of
      acute toxicities was conducted 3 months after the 14th non-ACC inclusion.

      ACC As the endpoint will be evaluated at 6 months after treatment start, a one-stage phase II
      study design was chosen. The unacceptable 6-month rate of progression free survival is 20%
      and the promising 6-month rate of progression free survival is 40%.

      43 patients are to be treated. If ≤12 patients alive without progression at 6 months will be
      observed, the drug will be declared ineffective.

      If ≥13 patients alive without progression at 6 months will be observed, the drug will be
      declared promising.

      The α error rate (accepting a poor treatment) is 0.07 and the β error rate (rejecting a
      promising treatment) is 0.07.

      Analysis of results will be separated between non ACC and ACC.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Salivary Gland Carcinoma</condition>
  <arm_group>
    <arm_group_label>pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pazopanib per os, 800mg daily until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pazopanib</intervention_name>
    <description>treatment will be given until progression or unacceptable toxicity .</description>
    <arm_group_label>pazopanib</arm_group_label>
    <other_name>Votrient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of recurrent and/or metastatic salivary glands
             (including ACC and non ACC)

          -  Progressive disease within 6 months before inclusion as assessed by CT and/or MRI
             using at least two measurements (RECIST V1.0) with at least one measurable target
             lesion &gt;10mm.

          -  Recurrent and/or metastatic salivary glands carcinoma failing locoregional therapy,
             without possibility of curative treatment.

          -  Patients may have had unlimited prior therapy but must have had at least 4-weeks
             between any chemotherapy, radiotherapy, surgery and study enrollment.

          -  Tumoral tissue must be provided for subsequent histological review and biomarker
             analysis.

          -  Euthyroidie patient

          -  Hepatic, Renal, cardiac and hematology normal functions

          -  Ability to take oral medication

        Exclusion Criteria:

          -  Non salivary gland carcinoma (lachrymal gland tumor is excluded)

          -  Known or symptomatic cerebral metastasis

          -  Patients treated with strong inhibitor or inductor of CYP3A4 within 14 days before
             inclusion

          -  Presence of uncontrolled infection

          -  Diagnosis of any previous malignancy within the last 5 years, except for completely
             resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma

          -  Stable disease

          -  Corrected QT interval (QTc)&gt; 480msecs using Bazett's formula
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Mr Guigay, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Lacassagne Nice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Val d'Aurelle Paul Lamarque</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier St Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie site St Cloud</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Cancérologie de l'Ouest</name>
      <address>
        <city>Saint-herblain</city>
        <zip>48805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>June 17, 2016</last_update_submitted>
  <last_update_submitted_qc>June 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual Participant Data (IPD) will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

